home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
  HUM-MOLGEN -> Events -> Meetings and Conferences  
 

Test Method Validation - The Characteristics - Webinar By GlobalCompliancePanel

 
  April 22, 2011  
     
 


GlobalCompliancePanel, Online Training Webinar
2011-05-19


Overview: Although the concept of test method validation is based on good science, the expectation that test methods in the pharmaceutical industry be validated was established by the USP in the 1980s and expanded as an international expectation for the industry with the publication of ICH Q2 in the mid 1990s.

Both USP <1225> and ICH Q2 classify test methods employed in the industry into types, based on the intended use and identify the characteristics that must be considered in the validation of each type of method.

In order to perform effective test method validations, the analyst must understand the importance of clearly identifying and understanding the intended use of the test method.  With the understanding of the intended use, the analyst will categorize the test method into one of the types identified in the USP and ICH Q2.  Based on the type of test method and using the guidance in the USP and ICH Q2 the analyst will identify the characteristics that must be considered for effective method validation.

For each characteristic, the USP and ICH Q2 recommend the experiments that the analyst should performed to demonstrate that the method performs as intended.

Why you should attend: The US FDA and other regulatory agencies are critically reviewing test method validations. Observations like: "Failure to establish accuracy, sensitivity, specificity, and reproducibility of test methods employed by your firm", which appear in Warning Letters and 483 observations demonstrate a complete lack of understanding of the regulatory expectations. Other observations that citing to the individual characteristics demonstrate a lack of appreciation for the contributions of the individual method characteristics on adequate method validations. In order to adequately validate test methods, firms must understand the basic terminology associated with test method validation. This webinar will provide an understanding of:
  • The types of test methods established by the USP and ICH Q2.
    • Assay
    • Identification
    • Testing for impurities – quantitative
    • Testing for impurities – limit
    • Performance
  • The characteristics of test methods as defined in the USP and ICH Q2.
    • Specificity
    • Accuracy
    • Precision
    • Linearity
    • Range
    • Limit of Accuracy
    • Limit of Detection
  • How the characteristics apply to the types of methods described in USP and ICH Q2.
  • The basics of how to experimentally evaluate the characteristics.
Areas Covered in the Session:
  • The requirement for test method validation
  • The intended use of the test method
  • Guidance documents covering test method validation
  • Types of test methods
  • Characteristics of test methods
  • Demonstrating the characteristics
Who will benefit: The following individuals or disciplines will benefit from attending this Webinar:
  • Quality Assurance personnel
  • Quality Control Managers
  • Quality Control Supervisors
  • Quality Control Analysts
  • Method development Managers
  • Method development Supervisors
  • Method Development Analysts
 
 
Organized by: GlobalCompliancePanel
Invited Speakers: John G. (Jerry) Lanese, Ph.D. CMC is the president of The Lanese Group, Inc, an independent consulting service provider that specializes in Quality Systems and Laboratory Controls. Jerry has taught at the college level and worked in various Quality Control and Quality Assurance roles in small and large pharmaceutical firms. For the last 15 years he has consulted in a wide range of projects from consent decree remedial actions with large pharmaceutical firms to systems development for a small component manufacturer. He has lectured throughout the world to clients and for major seminar providers. He was voted the best presenter of the year in 2001 by the Institute of Validation Technology. In 2008 he received the Kenneth Chapman Industry Recognition Award.
 
Deadline for Abstracts: 2011-05-19
 
Registration: Price List:
Live : $245.00
Corporate live : $995.00
Recorded : $295.00
E-mail: webinars@GlobalCompliancePanel.com
 
   
 
home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
 
 

Generated by meetings and positions 5.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995- HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.